Addition of Orteronel to ADT for Patients With Metastatic Hormone-Sensitive Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)
J. Clin. Oncol 2022 Apr 21;[EPub Ahead of Print], N Agarwal, CM Tangen, MHA Hussain, S Gupta, M Plets, PN Lara, AL Harzstark, PW Twardowski, CJ Paller, D Zylla, MR Zibelman, E Levine, BJ Roth, A Goldkorn, DA Vaena, M Kohli, T Crispino, NJ Vogelzang, IM Thompson, DI QuinnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.